Reversing endothelial dysfunction with empagliflozin to improve cardiomyocyte function in cardiorenal syndrome

Sodium-glucose cotransporter 2 inhibitors offer cardiovascular and renal benefits in patients with chronic kidney disease through not yet clearly defined mechanisms. Juni et al. showed that sodium-glucose inhibitor empagliflozin exposure vitro can restore cardiomyocyte function by counteracting harmful effects of uremic serum on the endothelium-cardiomyocyte crosstalk between endothelial cells cardiomyocytes. The author’s findings improved our understanding impairment provided new perspectives for beneficial therapy. Empagliflozin restores disease–induced regulation relaxation contractionKidney InternationalVol. 99Issue 5PreviewChronic (CKD) promotes development cardiac abnormalities is highly prevalent heart failure, particularly those preserved ejection fraction. CKD associated dysfunction, however, whether induce endothelium-to-cardiomyocyte leading to known. co-transporter inhibitor, empagliflozin, reduced events diabetic or without CKD, suggesting its potential as a treatment failure Full-Text PDF Open Access